REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors
Elevar Therapeutics
Elevar Therapeutics
Medivir
TransThera Sciences (Nanjing), Inc.
TransThera Sciences (Nanjing), Inc.
NextCure, Inc.
Novo Nordisk A/S
Klus Pharma Inc.
Basilea Pharmaceutica
SMT bio Co., Ltd.
Senhwa Biosciences, Inc.
Celgene
Rigshospitalet, Denmark
FeRx